Skip to main content
CLDX logo

CLDX · Celldex Therapeutics, Inc. · Documents

Track CLDX — free
$28.03 +0.48 (+1.72%) Q4 2021 earnings call transcript
Market Cap
$2.16B
Shares
78.55M
Volume · Nov 19 75.61K Avg daily vol (3M) 1.33M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.55M down 78.0% 10-K filed Feb 25, 2026 Quarterly report FY2026 Q3 Net loss $75.56M 10-Q filed Nov 5, 2026 Latest results Barzolvolimab CSU trials meet endpoints; BLA planned for 2027 8-K filed Nov 5, 2026 Earnings call Q4 2021 earnings call Held Feb 28, 2022
2026
Nov 5
Registration statement S-3ASR
Registers shelf for multiple securities offerings

Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.

Read from the first part of this long document
2 source passages
Celldex Therapeutics, Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination of: • our common stock, • our preferred stock, which we may issue in one or more series, • warrants, • depositary shares, and • units. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Phase 3 CSU trials meet endpoints, supporting 2027 BLA plan

Celldex Therapeutics, Inc. reported that two Phase 3 barzolvolimab studies in CSU met primary and all key secondary endpoints, with 1,939 patients enrolled; it plans to submit a BLA to the FDA in 2027.

Net loss $75.56M Diluted EPS -$0.96
Read from the MD&A section
3 source passages
In September 2026, we reported positive topline data from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab, which met primary and all key secondary endpoints. 1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. Based on these results, we plan to submit a BLA to the FDA in 2027. Open the document at this passage
Nov 5
Current report 8-K
Barzolvolimab CSU trials meet endpoints; BLA planned for 2027

Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 met primary and key secondary endpoints, supporting barzolvolimab in CSU, with a BLA submission planned for 2027. Celldex Therapeutics reported $650.3 million in cash, cash equivalents and marketable securities, funding planned operations through 2028.

Financial results
6 source passages
Celldex Therapeutics, Inc. In September 2026, the Company reported best-in-disease topline results from the Phase 3 EMBARQ-CSU1 and -CSU2 studies of barzolvolimab in patients with CSU whose symptoms are inadequately controlled by H1-antihistamines. The primary and all key secondary endpoints across both studies and both dose groups were met. Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027. Cash, cash equivalents and marketable securities as of September 30, 2026 were $650.3 million compared to $717.6 million as of June 30, 2026. Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028. Open the document at this passage
Sep 22
Current report 8-K
Other events

Celldex reported that barzolvolimab met primary and all key secondary endpoints at 12 weeks in two Phase 3 chronic spontaneous urticaria trials, with favorable safety through 24 weeks and a planned FDA BLA submission in 2027.

Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $22K ▼ 97.0% Net loss $73.5M Diluted EPS -$0.94
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $15K ▼ 97.8% Net loss $78.69M Diluted EPS -$1.18
Apr 29
Proxy statement DEF 14A Meeting Jun 25, 2026
Proxy statement AI summary on its way
Feb 25
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.55M ▼ 78.0% Net loss $258.76M Diluted EPS -$3.90
2025
2024
2023
Showing 1–50 of 102 documents
Key facts CIK 744218 CUSIP 15117B202 13F (30d) 267 filings 239 filers Visit website Investor relations